Novel thyrotropin-releasing hormone analogs: a patent review

Bibliography

• Guillemin R. Hormones secreted by the brain. Isolation, molecular structure and synthesis of the first hypophysiotropic hypothalamic hormone (to be discovered) TRF (thyrotropin-releasing factor). Science 1970;68:64-7
   Google Scholar
• Schally AV, Redding TW, Bowers CY, Barret JF. Isolation of porcine thyrotropin-releasing hormone. J Biol Chem 1969;244:4077-88
   Google Scholar
• Shinohaea S, Koike K. Antiparkinsonism drugs. US7129256B2; 2006
   Google Scholar
• Metcalf G, Jackson IMD. Thyrotropin releasing hormone: biomedical significance. Ann NY Acad Sci 1989;553:1-631
   Google Scholar
• O'Leary R, O'Connor B. Thyrotropin-releasing hormone. J Neurochem 1995;65(3):953-63
   Google Scholar
• Prokai L. Thyrotropin-releasing hormone analogues and their therapeutic applications. US20030232966Al; 2003
   Google Scholar
• Szirtes T, Kisfaludy L, Palosi E, Szporny L. Synthesis of thyrotropin-releasing hormone analogs. 1. Complete dissociation of central nervous system effects from thyrotropin-releasing activity. J Med Chem 1984;27(6):741-5
   Google Scholar
• Labroo VM, Cohen LA, Lozovsky D, Dissociation of the cardiovascular and prolactin-releasing activities of norvaline2-TRH. Neuropeptides 1987;10(1):29-36
   Google Scholar
• Monga V, Meena CL, Rajput S, Synthesis, receptor binding, and CNS pharmacological studies of new thyrotropin releasing hormone (TRH) analogues. ChemMedChem 2011;6(3):531-43
   Google Scholar
• Prokai-Tatrai K, Prokai L. Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents. Molecules 2009;14(2):633-54
   Google Scholar
• Giertz H, Barth H, Flohe L. Method of treating posttraumatic nervous injuries with dipeptide derivatives. US4906614; 1990
   Google Scholar
• Brewster D, Dettmar PW, Metcalf G. Biologically stable analogues of TRH with increased neuropharmacological potency. Neuropharmacology 1981;20(5):497-503
   Google Scholar
• Sarkadi A, Karpati E. TRH analogs at Gedeon Richter Ltd.: highlights of experimental and clinical efficacy of posatirelin. Acta Pharm Hung 2002;72(1):62-8
   Google Scholar
• Siren AL, Feuerstein G, Labroo VM, Effect of thyrotropin releasing hormone and some of its histidine analogs on the cardiovascular system and prolactin release in the conscious rat. Neuropeptides 1986;8(1):63-70
   Google Scholar
• Prokai-Tatrai K, Teixido M, Nguyen V, A pyridinium-substituted analog of the TRH-like tripeptide pGlu-Glu-Pro-NH2 and its prodrugs as central nervous system agents. Med Chem 2005;1(2):141-52
   Google Scholar
• Kelly JA, Slator GR, Tipton KF, Kinetic investigation of the specificity of porcine brain thyrotropin-releasing hormone-degrading ectoenzyme for thyrotropin-releasing hormone-like peptides. J Biol Chem 2000;275(22):16746-51
   Google Scholar
• Spatola AF, Lankiewicz L, Labroo VM, Vonhof S. Thionated analogues of thyrotropin releasing hormone. US5244884; 1993
   Google Scholar
• Veber DF, Nutt RF, Hirschmann RF. Tetrapeptide analog of TRH. US4066749; 1978
   Google Scholar
• Kelly J. Compounds that modulate TRH actions. US20070265202Al; 2007
   Google Scholar
• Bundgaard H, Moss J. Prodrug derivatives of thyrotropin-releasing hormone (TRH). US005405834A; 1995
   Google Scholar
• Prokai L, Ouyang XD, Wu WM, Bodor N. Chemical delivery system to transport a pyroglutamyl peptide amide to the central nervous system. J Am Chem Soc 1994;116(6):2643-4
   Google Scholar
• Prokai L, Prokai-Tatrai K, Ouyang X, Metabolism-based brain-targeting system for a thyrotropin-releasing hormone analogue. J Med Chem 1999;42(22):4563-71
   Google Scholar
• Yoon SH, Wu J, Wu WM, Brain-targeted chemical delivery of [Leu2, Pip3]-TRH: synthesis and biological evaluation. Bioorg Med Chem 2000;8(5):1059-63
   Google Scholar
• Prokai-Tatrai K, Nguyen V, Zharikova AD, Prodrugs to enhance central nervous system effects of the TRH-like peptide pGlu-Glu-Pro-NH2.. Bioorg Med Chem Lett 2003;13(6):1011-14
   Google Scholar
• Prokai L, Prokai-Tatrai K, Zharikova AD, Centrally acting and metabolically stable thyrotropin-releasing hormone analogues by replacement of histidine with substituted pyridinium. J Med Chem 2004;47(24):6025-33
   Google Scholar
• Bhatt U, Just G. Synthesis of a novel thyrotropin releasing hormone (TRH) analogue incorporating a piperazin-2-one ring. Helv Chim Acta 2000;83(4):722-7
   Google Scholar
• Teixido M, Prokai-Tatrai K, Wang X, Exploratory neuropharmacological evaluation of a conformationally constrained thyrotropin-releasing hormone analogue. Brain Res Bull 2007;73(1-3):103-7
   Google Scholar
• Prasad C. Bioactive cyclic dipeptides. Peptides 1995;16(1):151-64
   PubMed Web of Science ®Google Scholar
• Prasad C. Histidyl-proline diketopiperazine and method of use. US006090780A; 2000
   Google Scholar
• Wilber JF. Histidyl-proline diketopiperazine (Cyclo His-Pro) a CNS-active pharmacologic agent. USOO5418218A; 1995
   Google Scholar
• Faden AI, Knoblach SM, Cernak I, Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo. J Cereb Blood Flow Metab 2003;23(3):342-54
   PubMed Web of Science ®Google Scholar
• Faden AI, Fox GB, Di X, Neuroprotective and nootropic actions of a novel cyclized dipeptide after controlled cortical impact injury in mice. J Cereb Blood Flow Metab 2003;23(3):355-63
   PubMed Web of Science ®Google Scholar
• Faden AI, Movsesyan VA, Knoblach SM, Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology 2005;49(3):410-24
   PubMed Web of Science ®Google Scholar
• Kozikowski AP, Faden AI, Araldi GL. Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders. US7202279Bl; 2000
   Google Scholar
• Engel S, Neumann S, Kaur N, Low affinity analogs of thyrotropin-releasing hormone are super-agonists. J Biol Chem 2006;281(19):13103-9
   Google Scholar
• Kaur N, Lu X, Gershengorn MC, Jain R. Thyrotropin-releasing hormone (TRH) analogues that exhibit selectivity to TRH receptor subtype. J Med Chem 2005;48(19):6162-5
   Google Scholar
• Kelly JA. TRH-degrading ectoenzyme inhibitors. US7378397; 2008
   Google Scholar
• Scalabrino GA, Hogan N, O'Boyle KM, Discovery of a dual action first-in-class peptide that mimics and enhances CNS-mediated actions of thyrotropin-releasing hormone. Neuropharmacology 2007;52(7):1472-81
   Google Scholar
• Faden AI. Thyrotropin-releasing hormone analogs and method of use. US5686420; 1997
   Google Scholar
• Plotnikoff NP. Method of treating depression. US3737549; 1973
   Google Scholar
• Marangell LB, George MS, Callahan AM, Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 1997;54(3):214-22
   Google Scholar
• Szuba M, Fernando A, Winokur A, Gary K. Nocturnal TRH administration acutely ameliorates bipolar depression. Conference proceeding of the American College of Neuropsychopharmacology. San Juan, Peurto Rico; 1996
   Google Scholar
• Veber DF, Holly FW, Nutt RF, Varga SL. Analogs of thyrotropin-releasing hormone. US3959248; 1976
   Google Scholar
• Jaworska-Feil L, Kajta M, Budziszewska B, Protective effects of TRH and its stable analogue, RGH-2202, on kainate-induced seizures and neurotoxicity in rodents. Epilepsy Res 2001;43:67-73
   PubMed Web of Science ®Google Scholar
• Ogawa N, Hirose Y, Mori A, Involvement of thyrotropin-releasing hormone (TRH) neural system of the brain in pentylenetetrazol-induced seizures. Regul Pept 1985;12:249-56
   PubMedGoogle Scholar
• Kubek MJ, Garg BP. Thyrotropin-releasing hormone in the treatment of intractable epilepsy. Pediatr Neurol 2002;26(1):9-17
   PubMed Web of Science ®Google Scholar
• Momiyama T, Ishihara K, Kimura K, Long-term antiepileptic effects of chronic intake of CNK-602A, a thyrotropin-releasing hormone analogue, on spontaneously epileptic rats. Epilepsia 1996;37(4):328-31
   Google Scholar
• Takeuchi Y, Tominaga M, Mitsufuji N, Thyrotropin-releasing hormone in treatment of intractable epilepsy: neurochemical analysis of CSF monoamine metabolites* 1. Pediatr Neurol 1995;12(2):139-45
   Google Scholar
• Inanaga K, Nagawa Y. Antiepileptics. US4421745; 1983
   Google Scholar
• Jain R, Kaur N, Monga V. CNS effective thyrotropin releasing hormone analogs. WO2065DEL2006; 2006
   Google Scholar
• Kubek MJ, Domb AJ, Veronesi MC. Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles. Neurotherapeutics 2009;6(2):359-71
   Google Scholar
• Veronesi MC, Aldouby Y, Domb AJ, Kubek MJ. Thyrotropin-releasing hormone d, l polylactide nanoparticles (TRH-NPs) protect against glutamate toxicity in vitro and kindling development in vivo. Brain Res 2009;1303:151-60
   Google Scholar
• Veronesi MC, Kubek DJ, Kubek MJ. Intranasal delivery of a thyrotropin releasing hormone analog attenuates seizures in the amygdala kindled rat. Epilepsia 2007;48(12):2280-6
   Google Scholar
• Nishimura Y. The cerebellum of rolling mouse Nagoya. Adv Neurol Sci 1975;19:670-2
   Google Scholar
• Kinoshita K, Yamamura M, Sugihara J, Taltirelin hydrate (TA-0910): An orally active thyrotropin-releasing hormone mimetic agent with multiple actions. CNS Drug Rev 1998;4(1):25-41
   Google Scholar
• Isakson PC. Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor (s) and a second drug. US20040063751Al; 2003
   Google Scholar
• Engel WK. Treatment of neurologic functions. US4608365; 1986
   Google Scholar
• Caroscio JT, Cohen JA, Zawodniak J, A double blind, placebo controlled trial of TRH in amyotrophic lateral sclerosis. Neurology 1986;36(2):141-5
   Google Scholar
• Brooks BR. A summary of the current position of TRH in ALS therapy. Ann NY Acad Sci 1989;553(1):431-61
   Google Scholar
• Imoto K, Saida K, Iwamura K, Amyotrophic lateral sclerosis: A double-blind crossover trial of thyrotropin-releasing hormone. J Neurol Neurosurg Psychiatry 1984;47(12):1332-4
   Google Scholar
• Hawley RJ, Kratz R, Goodman RR, Treatment of amyotrophic lateral sclerosis with the TRH analog DN 1417. Neurology 1987;37(4):715-17
   Google Scholar
• Sharp T, Bennett GW, Marsden CA, Tulloch IF. A comparison of the locomotor effects induced by centrally injected TRH and TRH analogues. Regul Pept 1984;9(4):305-15
   Google Scholar
• Jaworska-Feil L, Jantas D, Leskiewicz M, Protective effects of TRH and its analogues against various cytotoxic agents in retinoic acid (RA)-differentiated human neuroblastoma SH-SY5Y cells. Neuropeptides 2010;44(6):495-508
   Google Scholar
• Ogata A, Nagashima K, Yasui K, Sustained release dosage of thyrotropin-releasing hormone improves experimental Japanese encephalitis virus-induced parkinsonism in rats. J Neurol Sci 1998;159(2):135-9
   Google Scholar
• Brewster D. Species variations in TRH inactivation: advantages of stable analogues. In: Griffiths EC, Bennett GW, editors. Thyrotropin-releasing hormone. Raven Press; New York: 1983. p. 109-18
   Google Scholar
• Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991;148(11):1474-86
   PubMed Web of Science ®Google Scholar
• Rang HP, Dale MM, Ritter JM, Moore PK. Rang & Dale's Pharmacology. 6th edition. Churchill Livingstone; London: 2007
   Google Scholar
• Wilson IC. Method of treating schizophrenia. US3932623; 1976
   Google Scholar
• Miyamoto M, Fukuda N, Narumi S, [gamma]-butyrolactone-[gamma]-carbonyl-histidyl-prolinamide citrate (DN-1417): a novel TRH analog with potent effects on the central nervous system. Life Sci 1981;28(8):861-9
   Google Scholar
• Brambilla F, Aguglia E, Massironi R, Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology 1986;15(3-4):114-21
   Google Scholar
• Gary KA, Sevarino KA, Yarbrough GG, The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J Pharmacol Exp Ther 2003;305(2):410-16
   PubMed Web of Science ®Google Scholar
• Mellow AM, Sunderland T, Cohen RM, Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. Psychopharmacology (Berl) 1989;98(3):403-7
   Google Scholar
• Molchan SE, Mellow AM, Lawlor BA, TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl) 1990;101(1):84-9
   Google Scholar
• Matsushita M, Yonemori F, Furukawa N, Effects of the novel thyrotropin-releasing hormone analogue Na-((1S, 2R)-2-methyl-4-oxocyclopentylcarbonyl)-L-histidyl-L-prolinamide monohydrate on the central nervous system in mice and rats. Arzneim Forsch Drug Res 1993;43(8):813-17
   Google Scholar
• Yamada H, Takeuchi S, Toide K, Iwata K. Effect and mechanism of action of a novel TRH analogue, JTP-2942, on Morris water maze spatial cognitive impairment in aged rats. Jpn J Pharmacol 1993;61:92-5
   Google Scholar
• Urayama A, Yamada S, Deguchi Y, Brain receptor binding characteristics and pharmacokinetics of JTP-2942, a novel thyrotropin-releasing hormone (TRH) analogue. Life Sci 1999;65(22):2407-15
   Google Scholar
• Atwater RM. Blakiston's New Gould Medical Dictionary. American Journal of Public Health. 2nd edition. McGraw-Hill; New York: 1956. p. 1092
   Google Scholar
• Holaday JW, Long JB, Martinez Arizala A, Effects of TRH in circulatory shock and central nervous system ischemia. Ann NY Acad Sci 1989;553(1):370-9
   Google Scholar
• Jantas D, Jaworska-Feil L, Lipkowski AW, Lason W. Effects of TRH and its analogues on primary cortical neuronal cell damage induced by various excitotoxic, necrotic and apoptotic agents. Neuropeptides 2009;43(5):371-85
   Google Scholar
• Veronesi MC, Yard M, Jackson J, An analog of thyrotropin-releasing hormone (TRH) is neuroprotective against glutamate-induced toxicity in fetal rat hippocampal neurons in vitro. Brain Res 2007;1128:79-85
   Google Scholar
• Holaday JW, D'Amato RJ, Faden AI. Thyrotropin-releasing hormone improves cardiovascular function in experimental endotoxic and hemorrhagic shock. Science 1981;213(4504):216-18
   Google Scholar
• Holaday JW. Thyrotropin releasing hormone in therapy of shock and as a central nervous system stimulant. US4426378; 1984
   Google Scholar
• Faden AI, Hallenbeck JM, Brown CQ. Treatment of experimental stroke: Comparison of naloxone and thyrotropin releasing hormone. Neurology 1982;32(10):1083-7
   PubMed Web of Science ®Google Scholar
• Holaday JW, D'Amato RJ. Naloxone or TRH fails to improve neurologic deficits in gerbil models of "stroke''. Life Sci 1982;31(4):385-92
   Google Scholar
• Faden AI. Neuropeptides and stroke: current status and potential application. Stroke 1983;14(2):169-74
   Google Scholar
• Faden AI, Jacobs TP, Holaday JW. Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. N Engl J Med 1981;305(18):1063-7
   Google Scholar
• Takahashi Y, Takeuchi K. Treating impaired consciousness with glutamyl-L-histidyl-L-prolinamide. US4059692; 1977
   Google Scholar
• Faden A. Thyrotropin-releasing hormone analogs in CNS injury. WO8809604; 1988
   Google Scholar
• Tyson JE, Method of employing oral TRH. US4125605; 1978
   Google Scholar
• Lotti VJ, Stone CA. Method of treating hypertension. US4215110; 1980
   Google Scholar
• Mock V, Atkinson A, Barsevick A, NCCN practice guidelines for cancer-related fatigue. Oncology 2000;14(11A):151-61
   PubMed Web of Science ®Google Scholar
• Prange AJ Jr, Yarbrough GG, Winokur A. Methods for treating cancer-related fatigue. US20060063703Al; 2006
   Google Scholar
• Reichlin S, Saperstein R, Jackson I MD, Hypothalamic hormones. Annu Rev Physiol 1976;38(1):389-424
   Google Scholar
• Basmaciogullari A, Cras-Meneur C, Czernichow P, Scharfmann R. Pancreatic pattern of expression of thyrotropin-releasing hormone during rat embryonic development. J Endocrinol 2000;166(3):481
   Google Scholar
• Yamada M, Saga Y, Shibusawa N, Tertiary hypothyroidism and hyperglycemia in mice with targeted disruption of the thyrotropin-releasing hormone gene. Proc Natl Acad Sci USA 1997;94(20):10862-7
   Google Scholar
• Luo LG, Jackson I. Thyrotropin releasing hormone (TRH) may preserve pancreatic islet cell function: potential role in the treatment of diabetes mellitus. Acta Biomed 2007;78(Suppl 1):216-21
   Google Scholar
• Konturek SJ, Tasler J, Jaworek J, Comparison of TRH and anorexigenic peptide on food intake and gastrointestinal secretions. Peptides 1981;2:235-40
   PubMed Web of Science ®Google Scholar
• Sugano H, Ishida R, Yamamura M. Novel peptides and processes for preparing the same. US4711878; 1987
   Google Scholar
• Sugano H, Ishida R, Yamamura M. Peptides and process for preparing the same. US4563306; 1986
   Google Scholar
• Metcalf G. Regulatory peptides as a source of new drugs: the clinical prospects for analogues of TRH which are resistant to metabolic degradation. Brain Res Rev 1982;4(3):389-408
   Google Scholar
• Kimura K, Ogasawara T, Mushiroi T. Histidylprolineamide derivatives. US4877784; 1989
   Google Scholar
• Yamamoto M, Shimizu M. Effects of a new TRH analogue, YM-14673 on the central nervous system. Naunyn Schmiedebergs Arch Pharmacol 1987;336(5):561-5
   Google Scholar
• Tamura T, Iwamoto H, Yoshida M, Yamamoto M. 4-Substituted-2-azetidinone compound. US4636567; 1987
   Google Scholar
• Tamura T, Iwamoto H, Yoshida M, Yamamoto M. 4-Substituted-2-azetidinone compound, process of producing the compounds, and medicaments containing the compounds. US4610821; 1986
   Google Scholar
• Tamura T, Yoshida M, Tsukamoto S, CNS active substituted azetidinone compounds. US4719207; 1988
   Google Scholar
• Nakamura E, Higuchi S, Terai M, Yamaguchi T. Metabolic fate of azetirelin. III, Transfer into the brain in rats. Oyo Yakuri 1991;41(3):227-34
   Google Scholar
• Sasaki I, Fujita T, Murakami M, Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. I: possible factors for the low oral bioavailability in rats. Biol Pharm Bull 1994;17(9):1256-61
   PubMed Web of Science ®Google Scholar
• Sasaki I, Tamura T, Shibakawa T, Metabolism of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue, by intestinal microorganisms. Pharm Res 1997;14(8):1004-7
   PubMed Web of Science ®Google Scholar
• Sasaki I, Tanaka K, Fujita T, Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II: in situ and in vitro absorption characteristics of azetirelin from the rat intestine. Biol Pharm Bull 1995;18(7):976-9
   Google Scholar
• Uchida I, Saito A, Yasuda A, Histidyl peptide derivatives. US5151497; 1992
   Google Scholar
• Haruta J, Sakuma K, Yasuda A, The synthesis and pharmacological activities of TRH analogues. Symp Med Chem Pharmacol Soc 1991;12:52
   Google Scholar
• Matsushita M, Yonemori F, Ohta A, Mechanism of hyperthermic effect of a novel thyrotropin-releasing hormone analogue N-[(1S,2R)-2-methyl-4-oxocyclopentylcarbonyl]-L-histidyl-L-prolinamide monohydrate in mice with reserpine-induced hypothermia. Arzneimittelforschung 1995;45:708-11
   Google Scholar
• Matsushita M, Yonemori F, Hamada A, Effect of JTP-2942, a novel thyrotropin-releasing hormone analogue, on pentobarbital-induced anesthesia in rats. Eur J Pharmacol 1995;276(1-2):177-82
   Google Scholar
• Uemura A, Yonemori F, Furukawa N, Effect of novel TRH analogue, JTP-2942, on various amnesia models in rodents. Jpn J Pharmacol 1993;61:187-9
   Google Scholar
• Katsumata T, Yonemori F, Katayama Y, Effect of JTP-2942, a novel TRH analogue, on cerebral blood flow and glucose utilization in rats with focal cerebral ischemia. Cerebrovasc Dis 1996;6:S48
   Google Scholar
• Katsumata T, Katayama Y, Ootori T, Effect of long-term administration of JTP-2942, a novel thyrotropin-releasing hormone analogue, on neurological outcome, local cerebral blood flow and glucose utilization in a rat focal cerebral ischemia. Brain Res 2001;901(1-2):62-70
   Google Scholar
• Katsumata T, Yonemori F, Katayama Y, Lasting effect of repeated administration of JTP-2942, a novel TRH analogue, on cerebral blood flow and glucose utilization in rats with focal cerebral ischemia. Cerebrovasc Dis 1996;6:S47
   Google Scholar
• Katsumata T, Katayama Y, Yonemori H, Delayed administration of JTP 2942, a novel thyrotropin releasing hormone analogue, improves cerebral blood flow and metabolism in rat postischaemic brain. Clin Exp Pharmacol Physiol 2001;28(1 2):48-54
   Google Scholar
• Yonemori F, Yamaguchi T, Nakayama H, Effect of JTP-2942, a novel thyrotropin-releasing hormone analog, on motor deficits after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000;20(1):74-81
   Google Scholar
• Nagai Y, Narumi S, Saji Y, Nagawa Y. A TRH analog (DN-1417). Blood level and brain distribution determined by radioimmunoassay after intravenous administration in rats. Nippon Yakurigaku Zasshi 1985;85(4):231-42
   Google Scholar
• Narumi S, Nagai Y, Saji Y, Nagawa Y. A possible mechanism of action of thyrotropin-releasing hormone (TRH) and its analog DN-1417 on the release of dopamine from the nucleus accumbens and striatum in rats. Jpn J Pharmacol 1985;39:425-35
   Google Scholar
• Nutt RF, Holly FW, Homnick C, Synthesis of thyrotropin-releasing hormone analogs with selective central nervous system effects. J Med Chem 1981;24(6):692-8
   Google Scholar
• Kisfaludy L, Szirtes T, Balaspiri L, Tripeptides acting on the central nervous system and a process for the preparation thereof. US4299821; 1983
   Google Scholar
• Oka M, Ochi Y, Furukawa K, L-6-ketopiperidine-2-carbonyl-2-carbonyl-L-leucyll-prolinamide as a novel thyrotropin-releasing hormone analogue with improving effects on impaired central nervous system functions. Arzneim Forsch Drug Res 1989;39:297-303
   Google Scholar
• Kaur N, Monga V, Josan JS, Synthesis, receptor binding, and activation studies of N(1)-alkyl-L-histidine containing thyrotropin releasing hormone (TRH) analogues. Bioorg Med Chem 2006;14:5981-8
   Google Scholar
• Kaur N, Monga V, Lu X, Modifications of the pyroglutamic acid and histidine residues in thyrotropin-releasing hormone (TRH) yield analogs with selectivity for TRH receptor type 2 over type 1. Bioorg Med Chem 2007;15(1):433-43
   Google Scholar
• Rajput SK, Krishnamoorthy S, Pawar C, Antiepileptic potential and behavioral profile of l-pGlu-(2-propyl)–l-His–l-ProNH2, a newer thyrotropin-releasing hormone analog. Epilepsy Behav 2009;14(1):48-53
   Google Scholar
• Khomane K, Kumar L, Meena C, NP-647, a novel TRH analogue: Investigating physicochemical parameters critical for its oral and parenteral delivery. Int J Pharm 2011;406:21-30
   PubMed Web of Science ®Google Scholar
• Monga V, Meena CL, Kaur N, Jain R. Chemistry and biology of thyrotropin-releasing hormone (TRH) and its analogs. Curr Med Chem 2008;15(26):2718-33
   Google Scholar
• Walter E, Kissel T. Transepithelial transport and metabolism of thyrotropin-releasing hormone (TRH) in monolayers of a human intestinal cell line (Caco-2): evidence for an active transport component? Pharm Res 1994;11(11):1575-80
   PubMedGoogle Scholar
• Yokohama S, Yoshioka T, Yamashita K, Kitamori N. Intestinal absorption mechanisms of thyrotropin-releasing hormone. J Pharmacobio Dyn 1984;7:445-50
   PubMedGoogle Scholar
• Lin CJ, Akarawut W, Smith DE. Competitive inhibition of glycylsarcosine transport by enalapril in rabbit renal brush border membrane vesicles: Interaction of ACE inhibitors with high-affinity H+/peptide symporter. Pharm Res 1999;16(5):609-15
   Google Scholar
• Kamath J, Yarbrough GG, Prange Jr AJ, Winokur A. The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis. Pharmacol Ther 2009;121(1):20-8
   Google Scholar